HC Wainwright Analysts Increase Earnings Estimates for TRVI

Trevi Therapeutics, Inc. (NASDAQ:TRVI) – HC Wainwright boosted their FY2024 earnings per share estimates for Trevi Therapeutics in a report issued on Monday, March 10th. HC Wainwright analyst O. Livnat now forecasts that the company will post earnings of ($0.48) per share for the year, up from their prior forecast of ($0.49). HC Wainwright currently has a “Buy” rating and a $12.50 price target on the stock. The consensus estimate for Trevi Therapeutics’ current full-year earnings is ($0.49) per share. HC Wainwright also issued estimates for Trevi Therapeutics’ Q1 2025 earnings at ($0.11) EPS, FY2026 earnings at ($0.57) EPS, FY2027 earnings at ($0.50) EPS, FY2028 earnings at ($0.39) EPS and FY2029 earnings at ($0.30) EPS.

Several other equities analysts have also recently issued reports on TRVI. D. Boral Capital reaffirmed a “buy” rating and set a $21.00 price objective on shares of Trevi Therapeutics in a report on Friday, March 7th. Raymond James upgraded Trevi Therapeutics from an “outperform” rating to a “strong-buy” rating and raised their price target for the company from $9.00 to $29.00 in a research report on Monday. Oppenheimer boosted their price objective on shares of Trevi Therapeutics from $12.00 to $20.00 and gave the stock an “outperform” rating in a research report on Tuesday. Finally, Needham & Company LLC raised their target price on shares of Trevi Therapeutics from $8.00 to $25.00 and gave the company a “buy” rating in a report on Monday. Seven investment analysts have rated the stock with a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $15.94.

Trevi Therapeutics Trading Down 0.2 %

TRVI stock opened at $6.29 on Thursday. The firm has a 50 day moving average of $4.30 and a 200-day moving average of $3.60. The company has a market cap of $483.49 million, a price-to-earnings ratio of -14.30 and a beta of 0.90. Trevi Therapeutics has a 12-month low of $2.30 and a 12-month high of $7.39.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of TRVI. GSA Capital Partners LLP acquired a new stake in shares of Trevi Therapeutics during the third quarter worth $409,000. Oppenheimer & Co. Inc. boosted its stake in Trevi Therapeutics by 34.7% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 81,947 shares of the company’s stock worth $274,000 after buying an additional 21,128 shares during the last quarter. MAI Capital Management boosted its stake in Trevi Therapeutics by 0.7% in the 3rd quarter. MAI Capital Management now owns 1,327,285 shares of the company’s stock worth $4,433,000 after buying an additional 8,789 shares during the last quarter. Intech Investment Management LLC purchased a new stake in Trevi Therapeutics in the 3rd quarter valued at about $63,000. Finally, BNP Paribas Financial Markets increased its stake in shares of Trevi Therapeutics by 130.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company’s stock valued at $40,000 after acquiring an additional 6,764 shares during the last quarter. 95.76% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Trevi Therapeutics

In related news, insider Farrell Simon sold 81,313 shares of the firm’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $6.75, for a total transaction of $548,862.75. Following the sale, the insider now owns 76,900 shares in the company, valued at approximately $519,075. This trade represents a 51.39 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 24.37% of the stock is owned by insiders.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.